Researchers evaluated 3,730 patients with heart failure with reduced ejection fraction and found that adding 10 mg of the SGLT2 inhibitor empagliflozin to standard of care led to a reduced risk for a composite of HF hospitalization or cardiovascular death among those with and without diabetes, compared with placebo. The findings will be presented at the European Society of Cardiology Congress.
Empagliflozin may benefit patients with HFrEF, diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.